Welcome to our dedicated page for GENMAB A/S SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GENMAB A/S's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GENMAB A/S's regulatory disclosures and financial reporting.
Genmab A/S has completed a share capital reduction approved at its March 19, 2026 Annual General Meeting. The company cancelled 1,900,000 of its own shares, each with a nominal value of DKK 1, reducing the total nominal share capital by DKK 1,900,000.
After this reduction, Genmab’s total share capital is DKK 62,350,721, represented by 62,350,721 shares of DKK 1 each, corresponding to the same number of votes. The change has been registered with the Danish Business Authority and will be reflected in Nasdaq’s systems, which the company expects on April 21, 2026.
Genmab A/S reports a major shareholder update involving Orbis Investment Management Limited. As of April 13, 2026, Orbis controlled the voting rights to 3,114,318 Genmab shares, equal to 4.85% of the share capital and voting rights. This represents a small decrease from a previously reported level of about 5.01%. The notice is made under Section 30 of the Danish Capital Markets Act and confirms Orbis’ position as a significant, but minority, shareholder in Genmab.
Genmab A/S reports that worldwide net trade sales of DARZALEX (daratumumab), as reported by Johnson & Johnson, reached USD 3,964 million in the first quarter of 2026. Net trade sales were USD 2,208 million in the U.S. and USD 1,756 million in the rest of the world.
Genmab receives royalties on these global DARZALEX sales under its exclusive worldwide license agreement with Johnson & Johnson to develop, manufacture and commercialize daratumumab.
Genmab A/S filed a Form 6-K detailing routine equity compensation events for several senior leaders. On April 1, 2026, restricted stock units vested into Genmab shares for President & CEO Jan van de Winkel, CFO Anthony Pagano and four other executive vice presidents. Each transaction is reported as an acquisition of shares due to vesting of restricted stock units, conducted outside the market at a reference price of DKK 1,758.50 per share. The filing is also incorporated by reference into Genmab’s existing Form S-8 registration statements.
Genmab A/S reports a major shareholder notification showing that Orbis Investment Management Limited controls the voting rights to 3,221,620 Genmab shares, equal to 5.01% of the company’s share capital and voting rights as of March 31, 2026.
The filing reflects a small increase from a prior 4.99% position and confirms that the holding is via shares only, with no additional voting exposure through financial instruments.
Genmab A/S has published a major shareholder notification showing that Orbis Investment Management Limited controls the voting rights to 3,205,763 Genmab shares, equal to 4.99% of the company’s share capital and voting rights as of March 27, 2026. This represents a small decrease from a previous reported position of 5.03% of voting rights. The issuer’s total voting rights and share capital are stated as 64,250,721.
Genmab A/S reports changes to its board leadership and new employee equity incentives. Following the Annual General Meeting, Deirdre P. Connelly was appointed Chair of the Board and Pernille Erenbjerg was appointed Deputy Chair.
The company decided to grant 5,213 restricted stock units and 4,485 warrants to employees of Genmab and its subsidiaries. Each restricted stock unit is awarded cost-free, has a fair value equal to the closing share price of DKK 1,645.00 at grant, and vests after three years subject to program conditions. Each warrant is also granted cost-free with an exercise price of DKK 1,645.00, has a fair value of DKK 530.62 based on the Black-Scholes formula, vests after three years, and expires seven years from the grant date.
Genmab A/S held its Annual General Meeting on March 19, 2026, where shareholders approved the 2025 Annual Report and gave discharge to the Board of Directors and Executive Management. The year’s profit of USD 963 million will be carried forward to retained earnings.
Six directors were re-elected for one year, and Deloitte was re-appointed as auditor. Shareholders also approved a reduction of the company’s share capital by nominally DKK 1,900,000 through cancellation of treasury shares. The proposal on 2026 Board remuneration was withdrawn, with a new proposal to be presented later.